Furthermore, we used rapamycin to block mTOR signaling to inhibit the proliferation and tumorigenesis of NPC cells and to assess its potential to inhibit CD44, SOX2 and OCT4 in cultured primary NPC cells and secondary tumors. The gene discussed is MTOR; the disease is nasopharyngeal carcinoma.